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Abstract
Beta thalassemia is the most frequent hemoglobinopathy worldwide. In patients with beta
thalassemia major (BTM), the consequence of long-term life-saving transfusions is iron
overload in liver, heart and endocrine glands. Hypogonadotropic hypogonadism is the
most frequent endocrine complication. Recent progresses in the treatment of BTM dra-
matically improved life expectancy and quality of life of these patients, making the con-
cern for fertility and pregnancy to gain importance. Therefore, we performed a review of
the available data regarding hypogonadism in female patients with BTM. We found that
hypogonadotropic hypogonadism is still frequently found in female patients with BTM.
Pituitary iron overload seems to be the main factor contributing to hypogonadism occur-
rence, although iron-related damage of the ovaries and the genital tract cannot be
excluded. The increased oxidative stress observed in BTM patients was hypothesized as a
contributor to pituitary-gonadal dysfunction. Hypogonadism has significant conse-
quences on quality of life, final height, bone health and fertility of the patients. Estro-
progestative administration is essential in order to minimize consequences, although the
best treatment regimen should be carefully weighted in each patient. Although spontane-
ous fertility is reduced by the presence of hypogonadism, it seems that ovulation-induc-
tion treatment with gonadotropins is effective in achieving pregnancies in majority of
patients.
Keywords: beta thalassemia, fertility, infertility, hypogonadism, pregnancy,
short stature, osteoporosis
1. Introduction
Beta thalassemia major (BTM) is a severe medical condition that requires long-term life-saving
transfusions. As a consequence, secondary hemosiderosis results in significant morbidity due
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to organ injury produced by excessive iron. Most frequently affected organs are heart, liver
and endocrine glands. While iron-induced cardiomyopathy is the most common cause of
death in BTM patients, endocrinopathies are among the most frequent complications, leading
to a low quality of life. In the last decades, increase of iron chelating agents’ availability and
better compliance to treatment with oral agents was followed by an increase in life expectancy
and a decrease of morbidity in BTM patients. However, the prevalence of endocrine complica-
tions remained high enough to significantly impact their quality of life. Hypogonadism is the
most prevalent endocrine complication in BTM patients and affects patients from various age
groups. The early forms of hypogonadism have a clinical impact starting at age of 10–11 years
as decreased growth velocity, short stature and delayed pubertal development. In pubertal
patients, the appearance of hypogonadism results in arrested pubertal development and lack
of sexual maturation. In adult patients with full pubertal development, the occurrence of
hypogonadism causes regression of secondary sexual characteristics, sexual dysfunction and
infertility. Therefore, hypogonadism has a significant psychological impact and is associated
with complications as infertility, osteoporosis and short stature which lead to additional
morbidity and medical care requirements. Early diagnosis and treatment of hypogonadism
has a particular importance for future fertility in female BTM in order to maintain the normal
genital tract and to avoid complications as short stature and osteoporosis which will interfere
with normal evolution of a future pregnancy.
Therefore, the aim of the present chapter was to perform a review of the available data
regarding the prevalence, physiopathology, consequences and treatment of hypogonadism in
female patients with BTM. We searched in PubMed and Google Scholar using the following
key words: beta thalassemia, fertility, infertility, hypogonadism, pregnancy, short stature and
osteoporosis. Only articles written in English were selected.
2. The prevalence of hypogonadism in BTM patients
Hypogonadism is the most frequent endocrine complication in BTM patients, the prevalence
being as high as 50–100% in various populations [1–4]. The high variability in the proportion of
patients affected by hypogonadism could be explained by ethnic factors, different availability
of therapeutic agents, economic status and genetic susceptibility. For example, in the study by
Gulati et al. [4], 10 of 11 BTM young patients (90%) from a developing country were presented
with early form of hypogonadism. In turn, a study on 382 BTM patients treated with desfer-
rioxamine at the Thalassemia Centre in Dubai showed a significantly lower prevalence of
hypogonadism of only 25% [5]. However, most studies reported a prevalence of hypogonadism
of approximately 50% [6].
In spite of significant progresses on the therapeutic regimens of thalassemia major aiming to
correct most of the factors considered responsible for BTM complications, hypogonadism
continues to be frequently found in these patients. Moreover, it seems that the prevalence was
not significantly reduced along with hematologic treatment improvement [7]. Gamberini et al.
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followed a cohort of 273 patients with BTM from diagnosis for 30 years in Ferrara Centre and
observed that, although the incidence of the other endocrine complications (hypothyroidism,
hypoparathyroidism and diabetes mellitus) has decreased over time, the proportion of patients
with primary and secondary amenorrhoea was similar in the three cohorts according to the
year of birth [7]. Moreover, the hypogonadism prevalence did not decrease along with the
decrease in serum ferritin over time, suggesting irreversible iron-induced lesions or an
increased susceptibility of pituitary cells to damages produced by excessive iron.
3. Etiopathogenesis of hypogonadism in BTM patients
3.1. Etiology of hypogonadism in BTM
Hypogonadism is defined as low levels of sex hormones as a consequence of decreased pro-
duction by the gonads. There are two types of hypogonadism: hypogonadotropic hypo-
gonadism (or secondary gonadal insufficiency) due to a pituitary defect in gonadotropins
production and hypergonadotropic hypogonadism (or primary gonadal insufficiency) due to
a defect in gonadal steroidogenesis. In both forms of hypogonadism, the clinical picture is the
same with amenorrhoea, regression of secondary sexual characteristics (breast, uterus and
vaginal atrophy) and hot flushes. In hypogonadal patients, the gametogenesis is also affected,
the consequence being anovulation and infertility. In BTM, most patients with hypogonadism
are presented with low gonadotropins levels indicating the presence of hypogonadotropic
hypogonadism [2]. Although these data support the existence of a pituitary defect, the coexis-
tence of an ovarian lesion cannot be excluded. However, the success of ovulation induction
with gonadotropins in hypogonadic female BTM patients shows that, if ovarian lesions coex-
ist, these are mild or reversible with a proper iron chelation as part of preconceptional care.
Iron overload is considered as the main factor involved in pathogenesis of hypogonadism in
BTM patients. This hypothesis is supported by several types of observations. For instance, most
studies reported an association of high serum ferritin levels with the presence of hypogonadism
[5, 8] or with a faster evolution to hypogonadism [8]. Serum ferritin level is considered an
accurate marker of tissue iron deposits, being correlated with T2* magnetic resonance imaging
of the heart, liver [8] and pituitary [9]. Moreover, magnetic resonance imaging showed that
pituitary iron and volume loss predict the presence of hypogonadism [10].
Whether the hypogonadism is reversible with a better chelation therapy is incompletely clari-
fied. In some of the studies, the recent serum ferritin was poorly correlated to the presence
of hypogonadism, suggesting that a previous deleterious effect of iron overload could not
be reversed by decreasing glandular iron [6]. However, the study by Chatterjee and Katz [11]
found that BTM patients with less severe iron overload and organ damage in the
hypothalamic-pituitary axis could present with potentially reversible hypogonadotropic hypo-
gonadism. In turn, patients with severe iron overloaded had an irreversible form of hypogo-
nadism [11].
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It was also suggested that the anterior pituitary has a high susceptibility to iron accumulation
that could be explained by the increased number of transferrin receptors in this tissue [12].
Other factors were observed to be associated with the presence of hypogonadism, being
possible contributors to its etiology. For instance, the study by Belhoul et al. demonstrated that
splenectomy is related to the presence of hypogonadism independently of ferritin levels [5],
the mechanism behind this association being unknown. It was also reported that the develop-
ment of hypogonadotropic hypogonadism is associated with the severity of the underlying
genetic defect in beta-globin synthesis gene [13, 14]. The most probable explanation is that the
patients with severe defects in hemoglobin synthesis require higher quantities of transfused
blood, followed by a more severe iron overload. Liver dysfunction, diabetes, hypothyroidism
[15] and lower hemoglobin levels [16] were also reported as possible contributors to
hypogonadism.
3.2. Mechanisms involved in hypogonadism occurrence in BTM
In patients with BTM, the excessive iron deposition in tissues, following chronic life-saving
transfusion regimens, generates an increase in non-transferrin bound iron. This form of iron
has high tissue toxicity due to the excessive production of the reactive oxygen species (ROS)
[17]. Because ROS have a pro-oxidant activity, the excessive production of ROS disrupts the
oxidants/antioxidants balance of the cells generating chronic oxidative stress [18]. Moreover,
the antioxidant mechanisms in BTM patients could be decreased, contributing to oxidative
stress. The antioxidative defense is performed by enzymic (superoxide dismutase, catalase,
and glutathione peroxidase) and nonenzymic systems (scavenging molecules endogenously
produced like GSH, ubiquinols and uric acid or derived from the diet, such as vitamins
C and E). In patients with BTM, the level of vitamin E, glutathione peroxidase and superoxide
dismutase [19], total antioxidant capacity [20], ascorbate, vitamin A, beta-carotene and lyco-
pene [20] were found to be significantly lower in comparison to controls [19, 21, 22],
supporting the existence of a decreased antioxidant defense. Microelements essential for the
function of the antioxidative enzymes were also reported to be decreased in BTM patients [20].
Moreover, HCV infection and hepatic dysfunction, frequently found in BTM patients, might be
involved in the depletion of antioxidant mechanisms [23, 24]. Growth hormone deficiency,
another common complication in BTM patients, is a condition recognized for its association
with increased oxidative stress [25], being a possible contributor to redox imbalance in BTM
(Figure 1).
As a consequence of chronic oxidative stress, the fatty acids in membranes of cells suffer a
peroxidation process, resulting cytotoxic products will impair cell function, protein synthesis
and DNA structure [26].
Although no direct evidence exists linking oxidative stress with gonadal dysfunction in BTM
patients, oxidative stress is a reasonable putative factor based on data demonstrating their
involvement in female fertility in general population. For example, in the study by Appasamy
et al. was showed that, in patients performing assisted reproduction, total antioxidant capacity
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was positively associated with follicular fluid estradiol levels [27], indirectly supporting that
oxidative stress might have a negative impact on follicular development. It was also suggested
that oxidative stress contribute to the decrease of fertility related to age [18] and that non-heme
iron deposits in ovarian stromal tissue is associated to oxidative stress-induced ovarian aging
[28]. Moreover, low level of antioxidants was found to be related to anovulation in women [29].
The indirect evidence that oxidative stress is involved in iron overload-related complications is
provided by interventional studies showing the supplementation of antioxidants as vitamin C
and E in children with BTM is followed by improved liver function [30]. However, similar
evidence regarding the improvement of female fertility in BTM following antioxidants admin-
istration does not exist.
The link between oxidative stress and iron overload in BTM is suggested by reports showing
that iron chelation agents desferrioxamine (DFO) and deferasirox are effective in decreasing
iron overload along with oxidative stress [31]. Similarly, the study by Kuppusamy et al. found
that chelating treatment is associated with lower oxidative stress in BTM patients [32].
Other mechanisms were also proposed to be involved in hypogonadism occurrence in BTM.
For example, some authors suggested that adipose tissue dysfunction due to iron toxicity
could contribute to hypogonadotropic hypogonadism occurrence through a perturbed leptin
Figure 1. The mechanisms hypothesized to be involved in the appearance of oxidative stress in beta thalassemia major.
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production [33, 34]. Liver dysfunction, diabetes and hypothyroidism were found to be associ-
ated to hypogonadism [15], probably contributing to its occurrence by perturbed hormone
metabolism [35].
Chronic hypoxia due to anemia could be another mechanism involved in pituitary-gonadal
dysfunction in BTM. In support of this hypothesis are the studies showing decreased gonado-
tropin secretion few days after arriving at moderate altitude [36]. Moreover, it was observed
that the fertility rate is lower in high altitude population in comparison to low altitude,
probably as a consequence of a different reproductive hormones profile [37]. Animal studies
show that exposure to high altitude hypoxia affects the development and function of corpus
luteum [38]. Moreover, in men hypoxemia due to obstructive pulmonary disease was associ-
ated with hypogonadism and low testosterone levels [39], probably by downregulation of
Figure 2. The etiopathogenesis of hypogonadism in beta thalassemia major.
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androgen biosynthesizing genes in the testis as demonstrated by studies in rats [40]. However,
similar effects of hypoxemia on ovary were not demonstrated (Figure 2).
4. Consequences of hypogonadism
4.1. Osteoporosis
Osteoporosis in BTM patients is one of the most frequent complications, multiple factors
contributing to their appearance, being a major cause of morbidity in these patients as well.
Hypogonadism is a widely recognized risk factor for secondary osteoporosis. However, in
patients with BTM, the contribution of hypogonadism to osteoporosis pathogenesis was
reported variable in different populations. The study by Anapliotou et al. showed that patients
with hypogonadism had the lowest bone mineral density (BMD) and the sex steroids serum
level was the only parameter related to BMD measurements [41]. Moreover, the patients who
received continuous sex steroid replacement therapy had a better increase of their BMD in
comparison to those with intermittent treatment [41].
Although genetic factors play a role in other types of osteoporosis, the study by Origa et al.
found no association of osteoporosis with specific polymorphisms in candidate genes (vitamin
D receptor, estrogen receptor, calcitonin receptor and collagen type 1 alpha 1) [42]. Instead, in
female patients, osteoporosis was strongly associated with primary amenorrhea [42].
Similar findings are reported by Tzoulis et al. who find no relationship of low bone mass with
vitamin D status, the only significant association observed in the multivariate analysis being
between hypogonadism and low BMD at the lumbar spine [43].
However, the study by Chatterjee et al. reported that, in comparison to premature ovarian
failure patients, those with BTM increased, but did not normalized their BMD following
hormone replacement therapy. The authors concluded that other factors contribute to osteopo-
rosis in patients with BTM [44]. Skordis et al. summarized the current knowledge about osteo-
porosis in BTM, highlighting the fact that GH-IGF 1 axis dysfunction, hypoparathyroidism,
hypothyroidism, diabetes and vitamin D deficiency are important contributors as well [45].
Therefore, osteoporosis in BTM should be considered a multifactorial condition, hypogonadism
being probably an important contributor to its appearance. All the contributors to osteoporosis
should be addressed in order to reduce the incidence and to optimize the effect of treatment.
4.2. Infertility
Although spontaneous pregnancy can be obtained by the female patients with BTM, most of
them are infertile. However, in most of the studies, pregnancies were obtained after ovulation
induction with gonadotrophins or assisted reproduction. Skordis et al. reported spontaneous
pregnancies among 34 patients with regular menstrual cycles and induced pregnancies in
patients with primary or secondary amenorrhoea [46]. In the study by Origa et al., pregnancy
was achieved with gonadotropins stimulation in 33 of 46 women with BTM [47]. Bajoria et al.
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reported their experience with 11 BTM patients undergoing assisted reproductive technology
(ART). They found that 60% of infertile female patients with BTM present with hypogona-
dotropic hypogonadism and respond favorably to gonadotropins administration [48],
suggesting that central hypogonadism is the main cause of infertility in these patients. More-
over, in patients with regular menstrual cycles, fertility is usually preserved [46]. All these data
suggest that pituitary dysfunction is the main cause of infertility and that the ovaries are
usually intact in BTM female patients. In the light of these data, although few other factors
were suggested as contributors to infertility, they do not seem to play a major role. Decreased
endometrial receptivity due to iron deposition [49] is one of the factors possibly involved in
infertility, although the evidences are limited. Only one study evaluated this aspect and
demonstrated the presence of hemosiderin deposits in the endometrial epithelium of three
patients with BTM [49]. The desferrioxamine administration resulted in reduction or disap-
pearance of hemosiderin depositions [49].
The integrity of the ovarian tissue in patients with BTM is a matter of debate. Singer et al. [50]
found that the ovarian reserve is preserved in most thalassemic patients younger than 30–35 years
old. In the same study, the circulating levels of anti-Müllerian hormone (AMH), an accurate
marker of ovarian reserve, were correlated with non-transferrin-bound iron, suggesting the
involvement of labile iron in the regulation of ovarian reserve [50]. In turn, the study by Chang
et al. demonstrated that the serum levels of AMH are lower in women with transfusion-
dependent β thalassemia than in age-matched normal controls, suggesting a reduced ovarian
reserve in the former [51]. Moreover, the serum AMH level in BTM patients was significantly
inversely related to the ferritin level. Therefore, both studies suggest that iron overload can
affect directly the ovaries, although the extent of the damage could vary depending on the
severity of iron excess.
Although the presence of oxidative stress in BTM is widely recognized, its deleterious effect on
oocyte maturation, fertilization, embryo development and implantation described in general
population [52, 53] is not clearly linked to fertility in BTM patients. The success of ovulation
induction with gonadotropins in hypogonadal patients suggests deleterious effect of iron
depositions and oxidative stress on ovaries is not severe enough to impair the response to
treatment. However, the hypothesis that preconceptional care of patients undergoing fertility
treatment, including intensive chelation therapy prior to pregnancy, could reverse mild ovar-
ian hemosiderosis and ovarian oxidative stress-related injuries should not be neglected. More-
over, patients referred for infertility treatment are selected in order to lower the risk of
complications during pregnancy and those with severe iron-related complications are
excluded. Therefore, the population of women treated for infertility is not completely relevant
for the general population of female BTM patients and definitive conclusions regarding
involvement of ovarian iron deposits in infertility should not be drawn.
4.3. Quality of life
The quality of life in patients with BTM was widely reported to be decreased due to affected
physical, emotional and social functioning. Hypogonadism seems to be an early and signifi-
cant contributor to decreased quality of life in BTM as suggested by a recent study which
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evaluated the quality of life in adolescent BTM patients [54]. The authors observed that BTM
adolescents had poor perception of their general health and scored significantly lower in all the
subscales compared with the controls [54]. The high prevalence of short stature and pubertal
delay was associated with lowest scores for physical and psychological domains [54],
suggesting the important contribution of these endocrine complications to decreased quality
of life of BTM patients. The siblings of BTM patients also scored significantly less in environ-
ment domain, probably reflecting the impact of BTM within families [54].
4.4. Short stature
Short stature is frequently found in patients with BTM, being variably reported in different
populations, with prevalence as high as 30% in female patients [55]. Skordis et al. reviewed the
growth disturbances in BTM patients [45]. They concluded that the etiology is multifactorial,
causative factors including hemosiderosis, hypoxia secondary to chronic anemia, chronic liver
disease, nutritional deficiencies, intensive iron chelating therapy, emotional factors,
endocrinopathies (hypogonadism, delayed puberty, hypothyroidism, disturbed calcium
homeostasis and bone disease) and dysregulation of the GH-IGF-1 axis [45]. The authors also
describe three phases of growth in BTM children: a first phase in which growth disturbance is
due to hypoxia, anemia, ineffective erythropoiesis and nutritional factors; a second phase
during late childhood during which growth retardation is mainly due to GH-IGF-1 axis
dysfunction probably secondary to iron overload; a third phase that starts after the age of
10–11 years when delayed or arrested puberty contribute significantly to growth failure [45].
A multicenter international study performed by Thalassaemia International Federation (TIF) in
2004 including 29 Centers and 3817 patients reported that short stature is present in 31.1% of
males and 30.5% of females. However, the prevalence of growth hormone deficiency was only
7.9% in males and 8.8% in females, suggesting that other causes contributes significantly to
height deficit [55]. In turn, delayed puberty was the most common endocrine complication
(40.5%) [55].
Delvecchio et al. reviewed 123 papers and concluded that disproportionate short stature is
frequent and aggravates at puberty because of the lack of growth spurt. Later on, partial height
recovery may occur. Long-term treatment with recombinant human growth hormone seems
ineffective to improve final height [56]. Therefore, short stature is associated with early forms
of hypogonadism rather than with growth hormone deficiency, supporting of involvement of
the former in the etiology of height deficit.
5. Treatment of hypogonadism
5.1. Hormone replacement treatment
The aim of the treatment of hypogonadism in female BTM patients is to maintain secondary
sexual characteristics, to increase the quality of life and to counteract the negative impact on
bone health. However, due to the complexity of conditions accompanying BTM, some
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particularity should be taken into account when treating hypogonadic BTM patients. The
sequential estrogen-progestogen regimens are the cornerstones of treatment in women with
hypogonadism. These can be administrated as combined oral contraceptives (COC) or hor-
mone replacement treatment (HRT). Depending on the preparation used the doses of estro-
gens vary, being higher in COC than in HRT, and the type of progestogen differs. The routes of
hormones administration might be also different, the estrogens being administrated orally,
vaginally or transdermally in most of the preparation. Progestogens can be administrated as
oral tables, transdermal patch or intrauterine devices. Natural progesterone is available for
oral, vaginal and transdermal routes. The major concern regarding the use of estro-
progestative in BTM patients is the risk of thromboembolic events which is a well-known
complication in COC and HRT users [57]. BTM is a condition characterized by an increased
risk for thromboembolism [58, 59], mainly due to thrombocytosis secondary to splenectomy
and to decreased production of anticoagulants due to chronic liver dysfunction. Therefore, the
risk of thrombosis associated to COC or HRT administration can be even higher in BTM
patients, although no study addressed this aspect. It was suggested that BTM patients with
cardiomyopathy, diabetes, liver function anomalies and hypothyroidism [59], splenectomy
and inadequate transfusion regimen [60] could have an increased risk of thromboembolic
events, representing potential categories of patients in which COC administration should be
avoided. However, among COC those containing newer progestin compounds (desogestrel,
gestodene, drospirenone and cyproterone acetate) were reported to be more thrombogenic in
comparison to older ones [61–63] and this aspect should be taken into account in BTM patients.
Moreover, estrogens administered transdermally seem to have no prothrombotic effect [63],
probably because the high estrogens concentrations in portal system generated by the oral
administration of estrogens are avoided. In turn, vaginal ring has a similar venous thrombo-
embolism (VTE) risk to third and fourth COC generation [63]. All these factors should be
weighted when the decision to administer estro-progestative preparation for hypogonadism in
a female BTM patient should be taken. Although a combined regimenwith transdermal estrogen
and natural progesterone may seem advantageous in BTM patients due to an assumed
decreased risk of thrombosis, no data proving that hypothesis are published. Moreover, strict
recommendations (COC versus HRT) in other categories of patients requiring hormonal replace-
ment like those with premature ovarian failure are not available. Meanwhile, a recently
published paper in International Network of Clinicians for Endocrinopathies in Thalassemia
and Adolescent Medicine (ICET-A) [64] recommend that the clinician should take into consider-
ation the United States Medical Eligibility Criteria (US MEC) for Contraceptive Use [65].
According to these criteria, no restriction exists for women with BTM, chronic hepatitis or with
non-complicated insulin-dependent or non-insulin-dependent diabetes. However, in women
with past VTE and known thrombogenic mutations (e.g., factor V Leiden; prothrombin muta-
tion; and protein S, protein C and antithrombin deficiencies) and in women with diabetes
associated with nephropathy, retinopathy or neuropathy, the risk is considered unacceptable if
the contraceptive method is used [64, 65]. In patients with cholelitiasis COC administration
represents a contraindication only in the presence of symptoms requiringmedical treatment [65].
Some specific recommendations are made by ICET-A for patients with BTM [64]. They recom-
mend that the physician should take into account the risk and benefits of estro-progestative
administration in each particular patient and thoroughly discuss with the patients before
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starting the treatment. Splenectomized patients should receive antiagregant or anticoagulant
therapy during estro-progestative administration. In acute liver disease, estro-progestative is
contraindicated, but their administration should be reinitiated after the acute episode has
passed. They also consider the transdermal estradiol in association with micronized progester-
one ‘the most physiologic regimen with the best safety profile’, being an option in women with
risk factors for venous thromboembolism [64].
In order to reduce the risk of treatment, it is recommended that the serum estradiol level
maintained approximately 100 pg/mL [66]. This level could be obtained with 25–50 μg 17β
estradiol administered transdermally [67].
In patients with delayed puberty, the treatment should be started with low doses of transder-
mal, oral or parenteral estrogens. No particular regimen was reported for BTM patients and
data from other populations can be used. The doses should be gradually increased (with
25–100% every 6 months) over 2–3 years to mimic normal puberty and progesterone should be
added when vaginal bleeding occur or after 2 years of estrogen administration [68]. The initial
proposed estrogens doses are: transdermal estradiol 3–7 μg/day, oral ethinyl estradiol 2 μg/day,
micronized oral 17β estradiol 0.25 mg/day and depot estradiol 0.2 mg/month [68]. The adult
doses that should be reached are: transdermal estradiol 25–100 μg/day, oral ethinyl estradiol
10–20 μg/day, micronized oral 17β estradiol 1–4 mg/day and depot estradiol 2 mg/month [68].
5.2. Infertility treatment
As a consequence of improved care of BTM patients and increased quality of life and life
expectancy, an increasing number of women with BTM desire pregnancy. The existing reports
show that in BTM women with normal gonadal function, the pregnancy can be obtained
spontaneously, while in hypogonadal patients fertility is usually retrievable [47, 48]. Patients
with BTM contemplating pregnancy should be addressed to a BTM-specialized preconception
care department. During evaluation, the fertility potential and the woman’s fitness for preg-
nancy should be assessed and the risks of pregnancy should be discussed. The iron overload
consequences and especially liver and heart involvement is the main target of preconception
evaluation, ensuring that associated conditions are stabilized and the potential of decompen-
sation during pregnancy is minimized. The associated medications should be reviewed in
order to exclude those with teratogenic risk and genetic screening of the partner should be
provided in order to reduce the risk of a hemoglobinopathy in the baby.
Although the hypogonadotropic hypogonadism is the cause of infertility in most of the
patients, a full evaluation is necessary in all the patients in order to identify associated causes
(tubal obstruction and male factor). The first line of treatment in infertile BTM female patients
with hypogonadism without other causes of infertility is ovulation induction with gonadotro-
pins. Although some studies raised the question whether ovaries are injured by iron overload,
most of the patients respond to this treatment [47]. There are no specific stimulation protocols
for BTM patients, standard regimens being usually effective. In case of repeated failure of
ovulation induction with gonadotropins or in couples with oligo/azoospermia or tubal infer-
tility, in vitro fertilization is indicated. Growth hormone deficiency is not infrequent among
adult BTM patients and can be involved in fertility treatment success in selected cases as
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suggested by Surbek et al. [69] in their study. Although in patients with BTM data are limited,
numerous experimental studies suggest that growth hormone acts on oocytes competence and
ovarian steroidogenesis. Moreover, in patients with poor response to assisted reproduction
growth hormone administration can improve the outcome of infertility treatment. In the light
of these data, future studies should clarify the utility of growth hormone administration in
infertile BTM female patients.
In conclusion, hypogonadism is still a frequent complication in BTM female patients having a
significant impact on their health and quality of life. Early diagnosis and treatment is essential
in order to prevent complications, although a careful evaluation of the risks and benefits is
necessary in every patient. Fertility is usually retrievable with treatment. However, the evalu-
ation of fitness for pregnancy and preconceptional improvement of health are of paramount
importance for optimal results.
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